Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 15Phase NA 11Phase 1/2 6Phase EARLY_PHASE1 3Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Lymphoid 9Gastrointestinal 5Sarcoma 4Breast 4Genitourinary 3CNS 3Plasma cell 2Myeloid 2Thoracic 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 94Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Biopsy × Gynecologic × Clear all
NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NRG Oncology

Phase 3 Active not recruiting
450 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡